Latest Intellectual Property News

Cyclopharm Limited reported a 17% revenue increase to a record $32.3 million in 2025, powered by a 226% surge in US Technegas sales. The company is accelerating its US rollout with plans for up to 300 installations in 2026, while advancing clinical trials beyond pulmonary embolism.

Optiscan Imaging reports a sharp 43% drop in revenue and a 43% rise in losses for H1 FY26, driven by restricted research funding in key markets. The company bolsters its balance sheet with a $17.75 million capital raise to advance clinical studies and regulatory approvals.

Aeeris Ltd has reported a return to profitability for the half-year ended December 2025, driven by a strategic restructure and the launch of its AWARE platform. The company also secured new customers and strengthened its technology-led revenue streams.

TrivarX Limited reported a $1.26 million half-year loss as it completed the acquisition of Stabl-Im brain imaging IP and validated its mental health screening technology in veterans. The company raised $4.2 million to fund clinical development and expand its diagnostic portfolio.

QuickFee Limited has reported a dramatic turnaround with a $36.45 million profit in H1 FY26, driven by the sale of its US Pay Now business and a strategic capital return to shareholders. Underlying operations show promising growth despite divestments.

Etherstack plc reported a robust FY2025 financial rebound with revenue soaring 70% to US$10.1 million, driven by major US project deliveries and a 62% rise in recurring support revenues. The company also turned EBITDA positive and secured key long-term contracts, setting the stage for strong growth in 2026.

Singular Health Group reported a 55% rise in net loss to $2.97 million for H1 FY2026, driven by share-based payments and strategic hires, while making significant progress in US commercial deployments and securing FDA clearance for its cloud-based 3D medical imaging platform.

Electro Optic Systems reported a 27% revenue drop to $128.5 million in FY2025 but posted a net profit of $18.6 million, boosted by the sale of EM Solutions. The company strengthened its position with key contract wins and acquisitions, including the UK-based Interceptor business and a conditional deal for MARSS.

Mesoblast Limited is set to release its half-year financial results and operational update, spotlighting its FDA-approved cell therapy and expanding international partnerships.

Arovella Therapeutics reported a 22% increase in half-year losses to $1.88 million while securing FDA acceptance of its IND application for lead asset ALA-101, paving the way for first-in-human trials.

PlaySide Studios has secured a global publishing agreement with Swedish developer MVRX Games for the upcoming co-op platformer 'Dew', aiming for a 2028 PC and console release. This deal marks a strategic expansion of PlaySide’s publishing portfolio, backed by a multi-million AUD investment.

PLS Group has acquired Calix’s stake in their joint lithium processing venture, gaining full ownership and operational control while securing a royalty-free licence for Calix’s calciner technology.